Migraine Prophylaxis

Erenumab for Episodic Migraine Prophylaxis: Current Evidence

Erenumab for Episodic Migraine Prophylaxis: Current Evidence

By

The monoclonal antibody erenumab has shown favorable results regarding efficacy and safety for the prevention of migraine.

Eptinezumab Effectively Reduces Migraine Frequency in Phase 3 Trial

Eptinezumab Effectively Reduces Migraine Frequency in Phase 3 Trial

By

Eptinezumab, an investigational treatment for migraine prevention, has met its pivotal Phase 3 trial primary endpoint of significant reduction in monthly migraine days vs placebo.

FDA Reviews Biologics License Application for Novel Migraine Prevention Treatment

FDA Reviews Biologics License Application for Novel Migraine Prevention Treatment

By

The Food and Drug Administration has accepted a Biologics License Application for the investigational migraine prevention treatment, galcanezumab.

Current and Emerging Behavioral Treatments for Migraine: Expert Q&A

Current and Emerging Behavioral Treatments for Migraine: Expert Q&A

By

Some patients with migraines prefer nonpharmacological approaches to treatment and for these patients, evidence-based behavioral treatments may be at least as effective for migraine prophylaxis as medication.

Migraine Medication Prescribing Patterns Across Racial Groups

Migraine Medication Prescribing Patterns Across Racial Groups

By

Migraine medication prescription patterns and quality of prescribed medications for migraine headache are similar between minorities and other racial groups.

Aimovig Under Review for Migraine Prophylaxis

Aimovig Under Review for Migraine Prophylaxis

By

The FDA has accepted for review the Biologics License Application for Aimovig for migraine prophylaxis in patients experiencing more than 4 migraine days per month.

Sign Up for Free e-Newsletters